Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ida Elisabeth Viller Tuxen

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
BJC Reports|November 8, 2024
Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancerAndreas Bjerrum, Andreas Frederik Henriksen, Ann Søegaard Knoop, et al.
Journal of Medical Genetics|June 9, 2026
Interpreting <i>TP53</i> variants: somatic mosaicism and <i>ERCC6L2</i>-driven clonal evolutionAmalie Noergaard Andersson, Anna Byrjalsen, Ida Elisabeth Viller Tuxen, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
BJC Reports|November 8, 2024
Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancerAndreas Bjerrum, Andreas Frederik Henriksen, Ann Søegaard Knoop, et al.
Journal of Medical Genetics|June 9, 2026
Interpreting <i>TP53</i> variants: somatic mosaicism and <i>ERCC6L2</i>-driven clonal evolutionAmalie Noergaard Andersson, Anna Byrjalsen, Ida Elisabeth Viller Tuxen, et al.
Pageof 1